These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26937956)

  • 1. Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
    Willenbacher E; Weger R; Rochau U; Siebert U; Willenbacher W;
    PLoS One; 2016; 11(3):e0147381. PubMed ID: 26937956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
    Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
    Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
    Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
    Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries.
    Abildgaard N; Anttila P; Waage A; Rubin KH; Ørstavik S; Bent-Ennakhil N; Gavini F; Ma Y; Freilich J; Hansson M
    Eur J Cancer; 2024 Apr; 201():113921. PubMed ID: 38377776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National Healthcare database (SNDS).
    Touzeau C; Quignot N; Meng J; Jiang H; Khachatryan A; Singh M; Taieb V; Chauny JV; Désaméricq G
    Ann Hematol; 2021 Jul; 100(7):1825-1836. PubMed ID: 33884454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
    Hájek R; Jarkovsky J; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Campioni M; DeCosta L; Treur M; Gonzalez-McQuire S; Bouwmeester W
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e219-e240. PubMed ID: 29793653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatments for renal failure due to multiple myeloma.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2016 Nov; 17(16):2165-2177. PubMed ID: 27646819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
    Dunavin NC; Wei L; Elder P; Phillips GS; Benson DM; Hofmeister CC; Penza S; Greenfield C; Rose KS; Rieser G; Merritt L; Ketcham J; Heerema N; Byrd JC; Devine SM; Efebera YA
    Leuk Lymphoma; 2013 Aug; 54(8):1658-64. PubMed ID: 23194056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
    Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.
    Hari P; Mateos MV; Abonour R; Knop S; Bensinger W; Ludwig H; Song K; Hajek R; Moreau P; Siegel DS; Feng S; Obreja M; Aggarwal SK; Iskander K; Goldschmidt H
    Leukemia; 2017 Dec; 31(12):2630-2641. PubMed ID: 28439109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
    Merz M; Kellermann L; Poenisch W; Tischler HJ; Kohnke J; Knauf W; Goldschmidt H
    Ann Hematol; 2017 Jun; 96(6):987-993. PubMed ID: 28409228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
    Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
    Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A
    Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
    Venner CP; Connors JM; Sutherland HJ; Shepherd JD; Hamata L; Mourad YA; Barnett MJ; Broady R; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Nitta J; Power MM; Toze CL; Smith CA; Song KW
    Leuk Lymphoma; 2011 Jan; 52(1):34-41. PubMed ID: 21133716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.